Navigation Links
Vyta Corp Announces Engagement of Dr. Nino Sorgente as Independent Consultant
Date:10/8/2008

DENVER, Oct. 8 /PRNewswire-FirstCall/ -- Vyta Corp (OTC Bulletin Board: VYTC) today announced that effective October 7, 2008, Dr. Nino Sorgente has been formally engaged as an independent scientific consultant to Vyta Corp. Dr. Sorgente was formerly Vice President of Research and Development at BIOAGRA, LLC, a joint venture, equally owned by Vyta Corp and Justin Holdings, Inc. On September 15, 2008, Vyta Corp announced its filing of foreclosure litigation against BIOAGRA, LLC. BIOAGRA, LLC manufactures, markets and distributes AGRASTIM(R), a proprietary all-natural, biologically active yeast Beta-1,3/1,6-D-glucan feed supplement.

"We are pleased to retain the services of Dr. Sorgente," said Paul H. Metzinger, President and CEO of Vyta Corp. "Dr. Sorgente is recognized as one of the leading Beta glucan researchers for his contributions to the cosmetic, medical and agricultural applications of Beta glucan."

About Vyta Corp

Vyta Corp, based in Denver, Colorado, is traded on the over-the-counter NASDAQ stock market (OTCBB: VYTC) as well as on the Frankfurt, Hamburg, XETRA and Munich Exchanges (OTC:VYTA).

In addition to its interest in BIOAGRA, LLC, Vyta Corp owns various patents and intellectual properties related to NCS(R) (NanoPierce Connection System) an advanced electronic connection system. For more information on Vyta Corp, please visit its website at http://www.vytacorp.com .

About BIOAGRA, LLC

BIOAGRA, LLC is based in Hinesville, Georgia, where it produces, markets and sells AGRASTIM(R), which is a purified, all natural, nontoxic yeast Beta 1,3/1,6-D-glucan product with a high bioactivity function that improves the immune systems of animals and humans. AGRASTIM(R) is also used to replace growth promotion antibiotics that are currently used in the feed of the beef and dairy cattle, equine, swine, poultry and aquaculture industries.

This announcement contain
'/>"/>

SOURCE Vyta Corp
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Disaboom Announces Preliminary Third Quarter Results
2. Medifast Announces Opening of First Franchise Clinic
3. SXC Health Solutions announces PBM certification from the HR Policy Association
4. ALL Care Dental Plan Announces Expansion to New Key States
5. ONA-PCE Announces Final Round of Endorsed Candidates for Ohio General Assembly
6. Alfred Taubman Announces New $22M Gift to U-M
7. Bull Continues Repositioning and Announces the Acquisition of its Medicaid Solutions Business in the United States by Ingenix
8. Volcano Corporation Announces the Relocation of Corporate Headquarters to San Diego
9. Vision Audio Inc. Announces New EASe Games Designed for Children with Autism
10. Information Management Solutions Provider OCI Announces Redesign of Corporate Web Site
11. Menopause Relief: Award-Winning Physician Announces New Cost Effective Drug-Free Guidelines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... biology team has created a new technology for ... could travel the body and selectively target cancer ... biological devices that monitor and modify human physiology ... However, no existing technology enabled bioengineers to build ... and respond in a customized fashion. , "The ...
(Date:4/17/2014)... 16, 2014) The cause of neuronal death in ... proposes that neurons may be mistaken for foreign invaders ... to the way autoimmune diseases like type I diabetes, ... The study was published April 16, 2014, in ... likely controversial, idea in Parkinson,s disease; but if true, ...
(Date:4/17/2014)... April 17, 2014 EcoHealth Alliance, a nonprofit ... issues, published a comprehensive review today examining the current ... virus. The review calls for improved global surveillance strategies ... the recent outbreak of Ebola in West Africa that ... countries of Guinea and Liberia. According to the ...
(Date:4/17/2014)... (17 April 2014) Population Council scientists and their partners ... stable, and can prevent the transmission of multiple sexually ... in animals: HIV, herpes simplex virus 2 (HSV-2), and ... first data that the gel is effective against multiple ... in the vagina against all three viruses of at ...
(Date:4/17/2014)... D.C. -- The world is less than 40 years ... implications for people and governments, according to a top ... the first time in human history, food production will ... of land, water and energy," said Dr. Fred Davies, ... security. "Food issues could become as politically destabilizing by ...
Breaking Medicine News(10 mins):Health News:Building 'smart' cell-based therapies 2Health News:Is Parkinson's an autoimmune disease? 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2Health News:Food shortages could be most critical world issue by mid-century 2
... conducted this study which was self funded. The sweetness ... of the sweetener. // The researchers questioned about 30 ... sweeteners and sweet substances. This was done to detect ... with each substance. Sugar was rated highest. Participants found ...
... with fish oil supplements in teenagers.,Durham County Council’s senior ... 25 teenagers who had been rated with moderate to ... omega-3 fish and omega-6 evening primrose oil over a ... students aged 12 to 15 also had a high ...
... Prime Minister, Shaukat Aziz has been urged by the Poultry ... the poultry industry//. The industry is under crisis over the ... flu scare and the earthquake that hit the country on ... President of the Lahore Chamber of Commerce and Industry (LCCI) ...
... developed at Leeds that will benefit at large in ... the next generation// of miniaturized computers. ,By suspending ... and Dr Yulong Ding have created ‘nanofluids’ which can ... In a central heating system, nanofluids could increase efficiency ...
... Court, would ensure that patients or their relatives would be ... demand. Until now, patients and family members have been facing ... doctor or hospital as they tend to treat it as ... it is their property and therefore refuse to give the ...
... jointly by University of California, Berkeley, and Chilean researchers says ... in drinking water are more likely to succumb to lung ... in their adult life. ,It was found that ... than normal if the child's mother also drank the arsenic-contaminated ...
Cached Medicine News:Health News:Sweet, Sweeter and Sweetest 2Health News:Poultry Industry Of Pakistan Stresses On Need Of Relief Package 2Health News:Arsenic in Drinking Water Predisposes Children To Lung Cancer in Later Life 2
(Date:1/15/2014)... 15, 2014 Tegra Medical is very pleased to announce ... its new Chief Executive Officer.  Mark was promoted from his ... overseen the company,s four facilities in Massachusetts ... King joined Tegra Medical in 2012 with 20+ years of ...
(Date:1/15/2014)... Jan. 15, 2014  According to Millennium Research Group ... intelligence, the United States ... markets will expand moderately through 2022, with embolization ... particular, increasing interest in drug-eluting beads (DEBs) and ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Advanced Drug Delivery Systems -- Focus on ... STUDY OBJECTIVES A ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... Halozyme Therapeutics, Inc. (Nasdaq: HALO ), ... the extracellular matrix for the endocrinology, oncology, dermatology, ... of patient dosing for a Phase 1 clinical ... human hyaluronidase enzyme (rHuPH20) as a subcutaneous (SC) ...
... (Nasdaq: ALXA ) today announced positive results ... loxapine). This Phase 3,clinical trial was conducted in ... 5 mg and 10 mg doses of AZ-004 met ... significant reduction in,agitation from baseline to the 2-hour post-dose ...
Cached Medicine Technology:Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme 2Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme 3Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial 2Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial 3Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial 4Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial 5Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial 6Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial 7Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial 8Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial 9Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial 10
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
Medicine Products: